© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Latest Conference Articles
Triple Agonist Retatrutide Associated with Weight Loss of up to 24% in 48-Week Phase 2 Trial
June 27th 2023
ADA 2023: Weight loss with the combination GLP-1/GIP/glucagon receptor agonist was as high as 30% in study participants who received the highest dose.
Oral Semaglutide 50 mg May be Effective Option for Obesity Treatment, According to OASIS 1 Study Authors
June 26th 2023
ADA 2023. Once-daily oral semaglutide 50 mg induced 15.1% weight loss in adults with overweight or obesity without type 2 diabetes vs placebo.
Oral GLP-1 Agonist Orforglipron Leads to ~15% Mean Body Weight Reduction in Adults with Overweight/Obesity
June 26th 2023
ADA 2023: The investigational oral GLP-1 RA resulted in weight loss comparable to injectable GLP-1 RA formulations and requires no food or water restrictions.
SURMOUNT-2: Tirzepatide Treatment Leads to Average 15% Weight Loss in Adults with T2D, Obesity
June 24th 2023
ADA 2023: SURMOUNT-2 findings show tirzepatide is associated with greater weight loss in adults with T2D than any other treatment studied to date.
“Triagonist” Therapy for Type 2 Diabetes and Comorbidities to be Previewed at 2023 ADA Scientific Sessions
June 23rd 2023
ADA 2023. Retatrutide, an investigational triple GLP-1/GIP/glucagon agonist, may provide benefits in liver fibrosis and obesity as well as in glycemic control.
Electronic “Nudges” Linking Flu Vaccination to Potential CV Benefits Boosted Uptake in Older Adults in Denmark
March 9th 2023
ACC 2023. Electronic nudges highlighting the potential cardiovascular benefits of flu vaccination led to a modest uptake in vaccination rates among older adults in Denmark, according to results of the NUDGE-FLU trial.
Ketogenic Diet Associated with Increased Serum Lipids, 2-fold Greater Risk of MACE
March 8th 2023
ACC2023. Risk for MACE was nearly 7-fold higher in participants on a keto diet whose LDL-C was already high compared with those on a standard diet with LDL-C in a normal range.
Bempedoic Acid May be Effective Alternative for Statin-intolerant Patients, According to Data from CLEAR Outcomes Trial
March 7th 2023
ACC 2023. In the CLEAR Outcomes trial, bempedoic acid reduced risk for major CV events by 13% compared with placebo in patients who had, or were at high risk for, CVD.
Likelihood of Optimal GDMT for Patients with T2D, ASCVD Increased with Multifaceted Clinic Intervention
March 7th 2023
ACC2023. For high-risk T2D patients not receiving optimal treatment for hyperlipidemia, hypertension, or hyperglycemia, intensive, multidisciplinary training for clinic staff could shift practice.
Mediterranean Diet Beneficial for Prevention of Heart Disease, Death in Women
March 3rd 2023
ACC 2023. The Mediterranean diet has a beneficial effect on the primary prevention of cardiovascular disease and death in women, according to new analysis.